Working 55 hours or more per week associated with higher risk of stroke
the ONA take:
Working 55 hours or more per week is associated with a 33% increased risk for stroke and a 133% increased risk for developing coronary heart disease compared with working a standard 40-hour week, a large study published in the journal The Lancet has shown.
For the systematic review, researchers from University College London in London, UK, sought to examine the effects of longer workup hours on cardiovascular disease up to mid-2014. The analysis included 603,838 people from 3 continents that participated in 25 studies.
Researchers found that people who worked 55 hours or more per week had a 13% increased of incident coronary heart disease compared with those working 35 to 40 hours per week. When researchers only included 528,908 from 17 studies, there was 1.3 times greater risk of stroke in people working 55 or more hours a week compared with those working standard hours.
"Health professionals should be aware that working long hours is associated with a significantly increased risk of stroke, and perhaps also coronary heart disease," Mika Kivimäki, Professor of Epidemiology at University College London, UK, said.
Working 55 hours or more per week is associated with a 33% increased risk for stroke and a 133% increased risk for developing coronary heart disease .
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- Patients With Urologic Cancer Need Psycho-oncologic Support to Manage High Stress
- E-cigarettes and Replacement Nicotine Therapy Safer Than Tobacco Use
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Patients Undergoing Multiple Systemic Therapies for Metastatic Prostate Cancer Expect a Cure
- FDA Grants Priority Review to Ceritinib for First-line Treatment of ALK+ NSCLC
- Overall Health Worse in African American Men Undergoing Active Surveillance For Prostate Cancer
- Clinical Benefit of Simtuzumab Inconsistent for Myelofibrosis
- Follow-up Rates in Active Surveillance for Prostate Cancer Higher in University-Based vs Safety-Net Hospitals
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|